Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 activation (CRISPRa) systems have enabled genetic screens in cultured cell lines to discover and characterize drivers and inhibitors of cancer cell growth. We adapted this system for use in vivo to assess whether modulating endogenous gene expression levels can result in functional outcomes in the native environment of the liver. We engineered the catalytically dead CRISPR-associated 9 (dCas9)-positive mouse, cyclization recombination-inducible (Cre) CRISPRa system for cell type-specific gene activation in vivo. We tested the capacity for genetic screening in live animals by applying CRISPRa in a clinically relevant model of liver injury and repopulation. We targeted promoters of interest in regenerating hepatocytes using multiple single guide RNAs (gRNAs), and employed high-throughput sequencing to assess enrichment of gRNA sequences during liver repopulation and to link specific gRNAs to the initiation of carcinogenesis. All components of the CRISPRa system were expressed in a cell type-specific manner and activated endogenous gene expression in vivo. Multiple gRNA cassettes targeting a proto-oncogene were significantly enriched following liver repopulation, indicative of enhanced division of cells expressing the proto-oncogene. Furthermore, hepatocellular carcinomas developed containing gRNAs that activated this oncogene, indicative of cancer initiation events. Also, we employed our system for combinatorial cancer genetics in vivo as we found that while clonal hepatocellular carcinomas were dependent on the presence of the oncogene-inducing gRNAs, they were depleted for multiple gRNAs activating tumor suppressors. Conclusion: The in vivo CRISPRa platform developed here allows for parallel and combinatorial genetic screens in live animals; this approach enables screening for drivers and suppressors of cell replication and tumor initiation. (HEPATOLOGY 2018; 68:663-676).
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A dvances in sequencing technology have catalogued gene expression levels, epigenetic states, and transcription factor binding sites of many cell types in human and mouse.
(1-4) Despite these efforts, the functions of a large number of mammalian genes and in particular their combinatorial effects remain unknown. Candidate gene approaches are labor-intensive, while elucidating epistatic gene interactions is difficult or impossible to perform using conventional mouse genetic methods. For these reasons, functional and combinatorial assays that can predictably alter the expression levels of multiple genes in Abbreviations: AAV-Cre, serotype 8 adeno-associated virus with thyroxin-binding globulin promoter driving Cre expression; Cas9, CRISPR-associated 9; Cre, cyclization recombination; CRISPR, clustered regularly interspaced short palindromic repeats; CRISPRa, CRISPR/Cas9 activation; dCas9, catalytically dead Cas9; ES, embryonic stem; FAH, fumarylacetoacetate hydrolase; gRNA, guide RNA; HA, hemagglutinin; TA, transcriptional activator.
specific cell types and link alterations to phenotypes in live animals will be extremely useful for the annotation of gene function. Furthermore, an in vivo platform that could screen and assess genetic interactions would greatly expand our knowledge of pathophysiology in the native environment of the organ of interest.
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) system from Streptococcus pyogenes has been adapted to study genetics in eukaryotes and has facilitated genetic manipulation of specific loci in numerous cell lines and in vivo to generate genetically modified organisms. The native form of Cas9 binds to single guide RNA (gRNA) sequences, which direct the protein to cDNA elements where the endonuclease domain cleaves the targeted locus. Whole-genome loss-of-function screens using the native form of Cas9 have been performed in cell lines, which have been transplanted into mice to study tumorigenesis. (5) Cas9 has also been used to induce tumorigenesis by targeting up to 10 different tumor suppressors in vivo in the mouse liver. (6, 7) These studies delivered plasmids containing gRNA expression cassettes by hydrodynamic injection, which leads to DNA delivery and transient expression in roughly 20% of hepatocytes. (8) However, transient expression of the wild-type Cas9 together with gRNAs results in permanent disruptions in the genome. Thus, although useful to model and compare a limited number of targeted mutations, scale-up of these systems to include large pools of gRNAs has been limited by difficulties in linking specific gRNAs to observed phenotypes as the gRNA coding sequences themselves are lost from >95% of induced tumors. (6) These systems are further limited by the cytotoxic disruption of essential genes or from genomic stress induced by DNA breaks. (9, 10) Thus, new in vivo screening methods are needed that are scalable and allow observed phenotypes to be linked to specific gRNAs. CRISPR/Cas9 activation (CRISPRa) combines a catalytically dead, mutant Cas9 (dCas9) with transcriptional activators to enable gRNA-mediated, locus-specific gene activation. (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) Rather than inducing DNA breaks, CRISPRa recruits RNA polymerase II in a site-specific manner to promote the expression of target genes, allowing gRNAs to be linked to specific outcomes. These "gain-of-function" systems have been used to screen for genetic drivers of a number of biological processes in human cell lines. (22) CRISPRa systems are now capable of producing several log-fold gene activation by (1) linking multiple different types of transcriptional activator domains to dCas9 (19, 22) or (2) fusing dCas9 to a repeating peptide array known as the "SunTag" domain. (20, 21) The SunTag domain allows for the docking of up to 10 copies of the VP64 transcriptional activator to the intended target. (20) CRISPRa is scalable genome-wide and has been employed in cell lines from multiple species. (23) Recently, a CRISPRa system was used for a genetic screen for drug resistance in an ex vivo mouse leukemia model system; however, this system employed cancer cell lines and therefore did not examine tumor initiation in vivo. (24) To our knowledge, CRISPRa has not yet been used in vivo in a whole-animal vertebrate system.
Herein, we developed an in vivo CRISPRa screening system and apply it to a liver injury and repopulation model, the fumarylacetoacetate hydrolase knockout (Fah -/-) mouse model of hereditary tyrosinemia. (25) (26) (27) Fah -/-mice undergo conditional, lethal hepatocyte injury from the accumulation of toxic metabolites of tyrosine. The injury is controlled by the administration of nitisinone, a drug that blocks an upstream enzyme to prevent liver injury. (25) Hydrodynamic tail vein injection of plasmids that contain an Fah cDNA transgene, followed by removal of nitisinone, leads to repopulation of the Fah -/-liver with hepatocytes that stably express FAH. (26, 27) In addition, any "cargo" genes on the plasmids will be expressed in repopulating hepatocytes as well. (27, 28) In this study, we applied CRISPRa to conduct parallel genetic screens during liver repopulation and demonstrate the intended activation of target gene expression. We find that our system allows for genetic epistasis experiments, showing that up-regulation of an endogenous oncogene locus promotes cell proliferation and initiation of carcinogenesis and conversely that targeting of tumor suppressors inhibits tumorigenesis in vivo. We present CRISPRa as a valuable resource for scalable combinatorial genetic screens in mice.
Materials and Methods

PLASMID VECTORS
We obtained the dCas9-SunTag sequence used previously in cell lines (pHRdSV40-dCas9-10xGCN4_v4-P2A-BFP, Addgene catalog no. 60903), (20) PCRamplified the dCas9-SunTag sequence using primers dCas9_FseI_F (5 0 -AGAAGGCCGGCCTACGCG-CGCCACCAT-3 0 ) and dCas9_FseI_R (5 0 -GCA-TGGCCGGCCCAAATTTTGTAATCCAGAGG-TTGA-3 0 ), and inserted it into the FseI site of the Rosa26 targeting vector Ai9 (Addgene catalog no. 22799) to construct pAi9-dCas9.
A mouse codon-optimized transcriptional activator (TA) sequence was based on Gilbert et al. (20) except that the green fluorescent protein sequence was removed. The cDNA was designed in silico and synthesized as a gene fragment, together with a downstream polyadenylation sequence and a U6 promotor for gRNA synthesis (Genewiz Corp, NJ), then inserted into plasmid pKT2/Fah-Cag//SB (27) to construct pKT2/Fah-TA//SB. The U6 promoter has two BspQI restriction sites downstream, which allows for sticky-end ligation of annealed oligonucleotides or digested PCR products containing gRNA sequences.
Based on a published computational design, (20) we obtained oligonucleotides for cloning of gRNA expression constructs targeting Myc, Tnfrsf1a, or controls (Supporting Table S1 ) and for Slc7a11 and Tp53 (Supporting Table S2 ). We annealed the oligos at a concentration of 0.1 lM in T4 DNA ligase buffer (Invitrogen). The ends were phosphorylated with polynucleotide kinase (New England Biolabs) for 60 minutes at 378C, followed by 15-minute heat inactivation at 658C. The annealed oligonucleotides were pooled at a concentration of 0.1 nM each, and 0.09 ng of this pool was ligated to 50 ng of BspQI-digested plasmid pKT2/FAH-TA//SB or plasmid pKT2/Fah-U6//SB, which were then used to transform Escherichia coli. Finally, we pooled up to 20,000 bacterial clones (for up to 500 times the average coverage per gRNA) and prepared plasmid DNA to generate TAlib1 and TAlib2, which represent pools of all possible plasmid clones (Sigma Maxiprep kit). For quality control, we picked and sequenced 20-46 random bacterial clones from each library, all of which contained the expected gRNA sequences. We analyzed the distribution of the gRNAs cloned in the plasmids and found that it was not different from expected for a random distribution.
DERIVATION OF THE dCas9
1
MOUSE STRAIN
The vector pAi9-dCas9 was electroporated into mouse embryonic stem (ES) cells, and neomycin selection was performed to obtain putative homologous recombinant clones. We used PCR and Southern blotting to identify ES cell clones with the correct integration of the construct and performed karyotyping of ES cell clones to screen for correct chromosome number (data not shown). Correctly targeted ES cells were then injected into hybrid B6SJL/F1 mouse blastocysts, followed by implantation into pseudopregnant female mice. The offspring were genotyped, and 14/16 mice were found to be chimeric for the targeted ES cells. Genotyping was performed with primers Rosa_Com
, yielding a specific PCR product at 251 bp for the gene replacement allele and 501 bp for the wild-type allele. The dCas9 1 mice were crossed with Fah -/-mice to obtain Fah -/-;dCas9 1 mice. All CRISPRa experiments were conducted using FAH-null, dCas9 heterozygous (Fah ;dCas9 1 mice were maintained on 7.5 lg/mL nitisinone (SOBI, Sweden) until the time of injection with plasmid libraries at 8-12 weeks of age. One week prior to injection of the plasmids, the mice were tail vein-injected with 10 11 particles of hepatocyte-tropic serotype 8 adeno-associated virus with a hepatocyte-specific thyroxin-binding globulin promoter driving cyclization recombination (Cre) expression (AAV-Cre) in 100 lL saline (AV-8-PV1091; Penn Vector Core). Plasmid pools (10 lg TAlib1 or TAlib2) were hydrodynamically injected into the tail vein as described. (27, 28) Nitisinone was removed after the injection, and mice were euthanized 1 or 2 months later.
IMMUNOHISTOCHEMICAL STAINING
Liver tissues were fixed overnight in 4% paraformaldehyde and then paraffin-sectioned (Penn Digestive Diseases Center Morphology Core). Immunohistochemistry was performed using standard protocols as described. (27, 28) For FAH staining we employed rabbit anti-FAH (ab81087; Abcam) and goat antirabbit for secondary antibody (Vector Labs). Because dCas9 has a hemagglutinin (HA) tag, we could stain tissues with a mouse anti-HA antibody (H3663; Sigma-Aldrich) and a rabbit antimouse immunoglobulin G1 secondary antibody (SAB3701173; Sigma-Aldrich). For MYC we used a rabbit anti-MYC antibody (sc764; Santa Cruz Biotechnology) and a goat antirabbit as the secondary antibody (Vector Labs). Staining was performed similarly using antibodies to yes-associated protein 1 (4912; Cell Signaling Technologies), alphafetoprotein (sc8108; Santa Cruz Biotechnology), osteopontin (AF808; R&D Systems), and Ki67 (RM9106; Thermo Scientific).
WESTERN BLOTTING
Tissues were lysed in buffer containing 20 mM trishydroxymethylaminomethane (pH 7.5), 137 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 1% Nonidet P-40, and 10% glycerol, supplemented with cOmplete Mini Protease Inhibitor Cocktail (Thermo Scientific) and benzonase (Novagen) at 12.5 U/mL. Lysates were rotated at 48C for 30 minutes. Lysates were centrifuged at 16,000g for 10 minutes, and 100 lg protein was subjected to electrophoresis using NuPAGE 4%-12% bis-trishydroxymethylaminomethane precast gels (Life Technologies). After transferring to nitrocellulose membrane, Ponceau S (Sigma) was used to stain the membrane and then washed away by trishydroxymethylaminomethane-buffered saline supplemented with 0.1% Tween 20. Nonfat milk (5%) in wash buffer was used to block the membrane at room temperature for 1 hour. Primary antibody (HA; Abcam ab9110) was diluted in 5% bovine serum albumin in wash buffer and incubated at 48C overnight. The membrane was washed three times with wash buffer, each for 10 minutes, followed by incubation of horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 hour, in 5% nonfat milk in wash buffer. The membrane was washed again three times and imaged by film or by GE Amersham Imager 600.
HIGH-THROUGHPUT SEQUENCING
DNA was extracted from approximately 400 mg fresh liver tissue per mouse using a column purification kit according to the manufacturer's recommendations (Machery-Nagel Corp.). Illumina sequencing libraries were prepared from the genomic DNA with two rounds of PCR of the gRNA sequences. The first round of PCR was performed using 5-10 lg of genomic DNA (from three Fah -/-;dCas9 1 mice and one Fah -/-control mouse repopulated for 4 weeks with TAlib1) or 5 ng TAlib1 (three replicates) and primers
, with 25 cycles of amplification and an annealing temperature of 588C. The resultant PCR product was purified with Ampure beads (Beckman Coulter, Inc.) or by gel extraction (Machery-Nagel Corp.). The second round of PCR was performed with Primer 1.1 (5 0 -AATGA-TACGGCGACCACCGAGATCT-3 0 ) plus Illumina standard index sequencing primers (New England Biolabs). Sequencing was performed on an Illumina MiSeq or HiSeq machine with custom primer KWgRNAcust-SEQ_F (5 0 -TTTCCCTTGTGGAAGGACGAAA-CACCG-3 0 ). The Fastq files were de-multiplexed to give raw read counts for each of the gRNAs for each sample. The proportions for each of the gRNA sequences for each of the samples were adjusted for the change in median value of the control gRNA (to account for a drop in the proportion of the control gRNA due to a rise in the proportion of Myc gRNA), then normalized to the average proportions of each gRNA in TAlib1 or TAlib2. In TAlib1 and TAlib2, one gRNA sequence of each type (three total, targeting control, Myc, and Tnfrsf1a) was more than 10-fold underrepresented in the raw sequence results for all experimental samples, so they were excluded from further analysis as outliers. These likely represented inefficient cloning from the oligonucleotide pools. Therefore, 37 gRNA sequences, 19 for control, 9 for Myc, and 9 for Tnfrsf1a, were included in the analysis for TAlib1 (Supporting Table S1 ). Similarly, a total of 57 gRNAs met the criteria for inclusion in the analysis for TAlib2, including 20 control, 9 Myc, 10 Tnfrsf1a, 9 Slc7a11, and 9 Tp53 gRNAs (Supporting Table S2 ).
RNA EXTRACTION AND QUANTITATIVE RT-PCR
Total RNA was extracted from liver or tumor tissue using the RNeasy kit (Qiagen). Superscript II reverse transcriptase was used for generating cDNA (Life Technologies). PCR was performed using SYBRGreen qPCR Master Mix on a Mx3000 PCR cycler (Agilent Technologies). Each reaction was performed in triplicate and normalized relative to the ROX reference dye, and median cycle threshold values were used for subsequent analyses. TATA-box binding protein was used to normalize mRNA expression level. The following primers were used: Myc (forward
STATISTICS
Analysis of variance was performed for the gRNA prevalence values for TAlib1 and Fah -/-;dCas9 1 mice and showed a value of P 5 0.00016 for a difference between the Fah -/-;dCas9 1 values, as a group, compared to TAlib1 input. We performed paired twotailed t tests to compare the difference in the corrected prevalence values for the gRNAs in TAlib1 and TAlib2 for groups of gRNAs: control, Myc, Tnfrsf1a, Slc7a11, and Tp53. Myc mRNA levels for the treatment groups were compared using a t test. Chi-squared tests, followed by Bonferroni adjustment for multiple comparisons, were performed to compare linkage of tumors to gRNAs targeting Myc, Tnfrsf1a, Slc7a11, and Tp53 with control gRNAs, using a cutoff value for tumor linkage of an individual gRNA of prevalence greater than 0.05 or 0.001. Both cutoff values gave highly significant results, showing enrichment of Myc and Slc7a11 gRNAs and depletion of Tnfrsf1a and Tp53 gRNAs compared to control gRNAs.
Results
DERIVATION OF A TISSUE-SPECIFIC CRISPRa PLATFORM IN MICE
To achieve target gene activation, the CRISPRa system needs three components to form a complex at a genomic locus: a gRNA complementary to the locus, the dCas9 protein, and a TA protein that binds to the SunTag domain of dCas9 (Fig. 1a) .
We first derived mice containing a Rosa26 gene replacement allele encoding a nuclease-deficient dCas9 gene fused to the SunTag domain, (20) with an upstream floxed stop cassette (loxP-stop-loxP), and termed these gene replacement mice Gt(ROSA)26-
" for short (Fig.  1b) . PCR genotyping confirmed the presence of the dCas9 1 allele (Fig. 1c) . Mice homozygous for the allele (dCas9
) were fertile and phenotypically indistinguishable from their control littermates.
Next, dCas9 1 mice were tested for the activity of the floxed stop cassette and for tissue-specific dCas9 protein expression. In order to remove the floxed stop cassette from the dCas9 allele in hepatocytes, AAVCre (29, 30) was injected intravenously into adult dCas9 1 mice. We found that dCas9 protein was expressed in the liver of mice injected with AAV-Cre but was not present in the heart, pancreas, or kidney; nor was it detectable in the liver of uninjected dCas9 1 mice (Fig.  1d) . Immunohistochemical staining of liver sections confirmed the expression of predominantly nuclear dCas9 in hepatocytes (Fig. 1e) . Thus, our dCas9 1 mouse exhibits tissue-specific and temporal control of expression in the liver and in any other mouse cell type for which a Cre driver is available.
CRISPRa SCREEN DURING LIVER REPOPULATION
Having established that the dCas9 protein is expressed specifically within hepatocytes upon injection of AAV-Cre, we next sought to facilitate CRISPRa-linked liver repopulation assays by crossing dCas9 1 mice to Fah -/-mice to produce Fah -/-;dCas9 1 mice. To prevent liver injury, these mice were provided with continuous nitisinone therapy until Fah-encoding plasmids were injected at 8-12 weeks of age.
To introduce the remaining components of the CRISPRa system, we derived Sleeping Beauty transposon-containing plasmids with gRNA, TA, and , respectively) and the wild-type allele. (D) Western blot using a probe for the HA epitope of dCas9, demonstrating expression of the protein in the liver of Fah -/-;dCas9 1 mice injected with AAV-Cre and absence of expression in heart, pancreas, and kidney tissues or in control animals (wild-type mice and Fah -/-;dCas9 1 mice uninjected with AAV-Cre). Ponceau S staining indicates even loading. (E) Immunohistochemical staining with HA antibody of dCas9 protein, showing tissuespecific expression in hepatocytes and nuclear localization. Scale bar, 100 lm.
Fah expression cassettes. After pooling, these plasmids were hydrodynamically injected into Fah -/-;dCas9 1 mice (see schema Fig 1a) . The TA protein is a fusion of the VP64 domain, a transcriptional activator derived from herpes simplex virus, with an antibody fragment that avidly binds to the SunTag epitope array, such that up to 10 copies are loaded onto each dCas9 protein. (20, 21) The design of the gRNA expression construct facilitates high-throughput sequencing for precise quantification of the read counts for each of the gRNA sequences within libraries. (13, 20) We used previously validated computational prediction tools to design gRNAs targeted to the transcription start sites of selected target genes. (31) Our initial plasmid library, which we term "TAlib1," included 10 gRNAs targeting Myc ( Fig. 2a; Supporting Table S1 ), 10 targeting Tnfrsf1a (Supporting Fig. S1 and Table S1 ), and 20 nontargeting control gRNAs (Supporting Table S1 ). (31) Thus, TAlib1 is a pool of 40 plasmids that express Fah, the TA construct, and a unique gRNA.
To test our dCas9 activation system, Fah -/-;dCas9 1 mice were injected with AAV-Cre to activate expression of the dCas9 protein in hepatocytes. After 72 hours, TAlib1 was hydrodynamically injected into either Fah -/-;dCas9 1 or Fah -/-mice, and nitisinone was withdrawn to initiate liver injury and repopulation. Four weeks postinjection, mice were euthanized and examined for CRISPRa activity during liver repopulation. 
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Western blot analysis detected dCas9 and TA protein in liver tissue, confirming that the CRISPRa components were present in the liver 1 month after injection of AAV-Cre and the plasmid library (Fig.  2b) . Next, we determined whether the target gene Myc was activated by the CRISPRa system and whether the localization of MYC protein coincided with repopulation nodules. FAH and MYC protein expression and localization were examined by immunohistochemistry of serial paraffin sections of liver tissue (Fig. 2c) . Nodules of FAH-positive hepatocytes were found in the livers, consistent with the clonal expansion of stably transduced hepatocytes seen with Sleeping Beautymediated gene therapy in Fah -/-mice (Fig. 2c, middle  column) . (27, 28, 32) MYC protein was strongly positive within the nuclei of hepatocytes in all three Fah -/-;dCas9 1 mice injected with TAlib1 but not in Fah -/-control mice. MYC expression corresponded with FAH-positive nodules, indicating a robust and specific activation of expression (Fig. 2c, right column) . Importantly, not all FAH-positive nodules displayed up-regulation of MYC, consistent with a gRNA-specific effect, as only 10 out of the 40 gRNAs in the TAlib1 pool were targeted to the Myc locus (Fig. 2c, yellow arrows) . Thus, our CRISPRa system successfully activates target gene expression in repopulating hepatocytes in vivo.
PROMOTION OF LIVER REPOPULATION BY CRISPRa INDUCTION OF Myc
Having confirmed that CRISPRa can induce MYC protein expression, we next interrogated whether there was a growth advantage imparted on hepatocytes with activated Myc by determining changes in gRNA sequence prevalence over the course of liver repopulation. An increase in gRNA prevalence represents a functional promotion of hepatocyte clonal expansion.
To this end, we recovered DNA from the repopulated liver and performed high-throughput sequencing of the gRNA sequences to assess the prevalence of each gRNA compared to the input plasmid pool for TAlib1. We found significant enrichment for gRNAs targeting Myc activation compared to control gRNAs (Fig. 3a) . There was no significant change in prevalence for gRNAs targeting Tnfrsf1a. We found that Myc gRNAs were enriched up to 10-fold compared to a Fah -/-control mouse or the input plasmid pool (Fig. 3b) .
To confirm our findings and to assay additional target genes, we engineered a second plasmid pool that included gRNAs to activate Slc7a11 and Tp53 (10 gRNAs each) (TALib2; Supporting Table S2 ). Slc7a11 was selected for further study based on our results showing that this gene, which functions in glutathione metabolism, is massively up-regulated in repopulating hepatocytes in Fah -/-mice (A. Wang et al., unpublished data). Tp53 was selected as a potential negative regulator of carcinogenesis. (33, 34) As with the above experiment, Fah -/-;dCas9 1 mice were first injected with AAV-Cre to activate dCas9 expression, followed by hydrodynamic injection of TALib2 and withdrawal of nitisinone. The mice were allowed to repopulate for 1-2 months. Examination of bulk liver tissue for gRNA prevalence changes at 2 months using high-throughput sequencing again showed significant enrichment of multiple gRNAs targeting Myc (Fig. 3c) . We conclude that our in vivo dCas9 activation system activated the Myc locus in hepatocytes and accelerated repopulation by these cells, as measured by enrichment in the corresponding gRNA sequences compared to the control gRNAs.
CRISPRa INDUCTION OF MYC EXPRESSION LEADS TO LIVER CARCINOGENESIS
We observed that mice treated with either TAlib1 and TAlib2 developed one or more liver tumors following repopulation (Fig. 4a) . In one of the three Fah -/-;dCas9 1 mice treated with TAlib1 we detected a tumor of compact, dysplastic-appearing cells that were strongly positive for FAH and MYC (Fig. 4b, top  row) , indicating that CRISPRa activation of the endogenous Myc locus was linked to the initiation of
10 672 hepatocyte carcinogenesis. The tumor tissue was highly proliferative, as indicated by a large number of Ki-67-positive cells, and stained positive for markers of aggressive hepatocellular carcinoma including alphafetoprotein, osteopontin, and yes-associated protein 1 (Fig. 4b, bottom row) . With TALib2, two out of three mice euthanized at 1 month and three out of three mice euthanized at 2 months were found to have developed hepatic tumors. No tumors were observed in control Fah -/-repopulated with the library, as reported for Fah -/-repopulated with FAH plasmids. (27, 32) To quantify the degree of Myc activation, we performed quantitative RT-PCR on liver tissue from a C57B6 wild-type mouse, from control Fah -/-mice repopulated with Fah-expressing plasmids, from Fah -/-;dCas9 1 mice repopulated with TAlib1 or TAlib2, and from liver tumors of Fah -/-;dCas9 1 mice treated with TAlib2 (Fig. 4c) . The results showed an average 23-fold induction of Myc mRNA in bulk liver tissue from mice repopulated with the CRISPRa library (P < 0.05) and more than 300-fold induction of Myc mRNA in tumors (P < 0.05).
Next, we extracted genomic DNA from liver tumors and performed high-throughput sequencing of the gRNA sequences to determine which of them were linked to each tumor. We found that all tumors contained linked Myc gRNAs, indicating that tumors could not form without CRISPRa activation of the Myc locus (Fig. 4e) . The tumors averaged 4.6 unique gRNA sequences (range 2-7), and the proportions of each of the gRNAs linked to the tumors were consistent with clonality (Fig. 4e) . For example, the CRISPRa tumor pie chart shown in Fig. 4d illustrates a tumor that contained seven unique gRNA insertion events, including two separate events for the same Myc gRNA, which resulted in twice the number of sequencing reads for this gRNA compared to the other gRNA sequences (Fig. 4d, right panel) . Chi-squared testing indicated that, compared to the control gRNA sequences, there was a highly significant enrichment in Myc and Slc7a11 gRNA sequences in the tumors, while Tp53 and Tnfrsf1a gRNAs were significantly depleted (P < 0.001 for all comparisons).
To conclude, our results demonstrate that CRISPRa can initiate hepatocellular carcinomas in our mouse liver injury model by activating high levels of endogenous Myc expression. Importantly, because the initial hydrodynamic injection results in multiple Sleeping Beauty-mediated integration events in each hepatocyte clone (4.6 on average), our system allows for the assessment of combinatorial effects in each clonal tumor. Thus, we discovered that Myc-driven hepatic tumorigenesis is strongly inhibited by simultaneous activation of Tp53 and Tnfrsf1a as tumors were significantly depleted for gRNA sequences that target these genes (P < 0.001 for each comparison). This confirms the capacity of our CRISPRa system for performing genetic screening and epistasis assays in vivo.
Discussion
The results presented here demonstrate functional, parallel, and combinatorial genetic screening in vivo using a CRISPRa platform in mice. Multiple independent gRNAs activated Myc expression to give a robust The results demonstrate enrichment for Myc gRNAs over the course of repopulation and tumorigenesis. CRISPRa tumors are noted to have a quantal distribution of the gRNA prevalence, indicating that the tumor originates from a single clone. In this example, seven gRNA insertion events are predicted to have occurred: two for one of the Myc gRNAs (largest sector), two additional unique Myc gRNAs, two control gRNAs, and one Slc7a11 gRNA. (E) Heatmap of the prevalence of each gRNA (rows) in each tumor (columns) collected from mice repopulated with the CRISPRa system. Myc gRNAs were found to be linked to all of the tumors. Also, compared to control gRNAs, Myc and Slc7a11 gRNAs are significantly enriched in tumors, whereas Tp53 and Tnfrsf1a gRNAs are significantly depleted (P < 0.001 for each comparison by chi-squared test). Note that the rightmost two columns show that a single tumor has an identical gRNA linkage pattern when two different parts of the tumor were sampled, indicating homogeneity in the linkage of gRNAs throughout the tumor. Abbreviations: AFP, alpha-fetoprotein; H&E, hematoxylin and eosin; OPN, osteopontin; YAP1, yes-associated protein 1. growth phenotype in a liver repopulation model. The phenotype is analogous to what we previously observed with Myc cDNA overexpression. (28) Indeed, it was shown that liver-directed Myc cDNA overexpression in transgenic animals resulted in hepatocellular carcinoma by 12-15 months. (35) In our mice, carcinoma development occurred much more rapidly, likely due to the liver injury and repopulation that occurs in Fah -/-mice, which requires multiple rounds of hepatocyte cell division, and due to the high level of activation of Myc expression achieved in our system.
Myc expression was the result of gRNAs that directed dCas9 and VP64 to the transcriptional start site of Myc. Myc is induced in many, if not most, human cancers. In addition, it is up-regulated during liver regeneration after two thirds partial hepatectomy (36, 37) and liver repopulation in Fah -/-mice (A. Wang et al., unpublished data). Myc expression levels are controlled by transcriptional activators such as by BRD4, (38, 39) by phosphorylation and subsequent proteosomal degradation, (40) and by interaction with the protein AURKA. (41) Our results demonstrate that the level of transcription from the endogenous Myc locus can be modulated using the Cas9 activation system in vivo and that enhanced expression leads to a dramatic physiological impact on repopulation and carcinogenesis. Thus, Myc expression levels-normally tightly controlled in repopulating hepatocytes-can be significantly altered by the CRISPRa platform.
In contrast to the effect of Myc on promoting repopulation, we did not observe significant changes in gRNAs directed to Tnfrsf1a, Slc7a11, or Tp53 loci during liver repopulation. However, both Myc and Slc7a11 gRNAs were significantly enriched in tumors, whereas Tnfrsf1a and Tp53 were strikingly depleted. The results suggest that activation of these loci had a strong epistatic impact on Myc-dependent tumorigenesis. Previously, we had found that TNFR1 cDNA overexpression with a strong chicken beta-actin promoter blocked liver repopulation in Fah -/-mice, which was not observed with the CRISPRa platform. (28) It is possible that the level of expression of TNFR1 with the cDNA was greater than that with dCas9 system used here. Another possibility for the discrepancy is that the Myc and TNFR1 up-regulation overlapped within most hepatocytes in the present study as hepatocytes took up more than four gRNAs on average, such that the positive effect on growth directed by Myc overrode or masked the negative effects of TNFR1 up-regulation. Importantly, gRNAs activating Tnfrsf1a blocked Myc-driven tumorigenesis, suggesting that targeting of this cell surface receptor could be used as a therapy to prevent or treat hepatocellular carcinomas in humans. Future experiments with larger, more complex libraries will be necessary to fully delineate which genes can drive liver repopulation in the setting of injury and tumorigenesis. Thus, we are currently developing screens in which all genes in specific pathways can be interrogated simultaneously, by targeting all relevant gene promoters with guide RNAs. The size of the pooled libraries that can be screened depends on the efficiency of stable integration of transposons expressing single gRNAs. Hydrodynamic injection of Sleeping Beauty transposons into Fah -/-mice leads to stable integration of the transposon in up to 1 in 100 hepatocytes. (32) Given that an adult mouse has roughly 10 8 hepatocytes, up to 10 6 unique clonal events can be analyzed in a single animal. Therefore, we estimate that a pooled plasmid library with a complexity of 10,000 unique gRNAs targeting 2,000 genes with five gRNAs each could achieve an average of 100-fold representation in a single mouse, enabling high-throughput pathway and gene set analyses for biological processes in the liver.
Our data on the epistatic relationship between Myc and Tp53, demonstrating that Myc-driven tumors that also express high levels of p53 are at a selective disadvantage, establish that our system can be used to analyze epistatic relationships between the genes that are part of the screen. In the future, larger libraries of gRNA could be employed to determine which genes promote and which inhibit Myc-driven tumors. These data will be complementary to transcriptome profiling of liver tumors, which by definition captures all changes in the gene expression profile in hepatocellular carcinoma, whether they are primary drivers or secondary consequences of the neoplastic process.
We demonstrate that our dCas9 allele has exquisite tissue specificity that is dependent on the removal of a stop cassette by Cre. We envision that our system will be useful for performing additional tissue-specific genetic screens as dCas9 can be activated in any tissue of interest. We showed hepatocyte specificity with an AAV-Cre virus, but viruses with other cell type-specific tropisms could be used to target other tissues, such as the hematopoietic system, heart, or brain. Another method for tissue-specific activation is with transgenic mice harboring tissue-specific promoters driving Cre expression, such as Villin-Cre for intestine-specific expression. (42) The TA and gRNA sequences could be provided to target tissues with lentiviral or electroporation techniques or in lipid formulations. The dCas9 1 mouse strain could also be used for performing screens on cultured primary cells such as mouse embryonic fibroblasts, stem cells, blood cells, and hepatocytes.
The types of screens that will be able to be performed using mouse tissues with our system are limitless. Growth and tumorigenesis assays in vivo are especially promising. These data could be integrated with expression analysis to identify true "drivers" of tumorigenesis-genes that are overexpressed and contribute to tumorigenesis-as opposed to "passenger" genes-genes that become overexpressed in tumors but have no effect when the expression is targeted. The driver genes will make for excellent targets for cancer prevention or treatment.
